News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The One Simple Reason Investors Should Still Steer Clear Away From Valeant (VRX)



8/25/2017 6:30:37 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Over the past two years, only a small handful of publicly traded companies have the distinction of losing more than 90% of their value. Drugmaker Valeant Pharmaceuticals (NYSE:VRX) finds itself in that mix, having shed about 94% of its value since peaking in early August 2015 at $264 a share.

Valeant has faced a cadre of issues along the way, including allegations of wrongdoing by one of its online drug distributors, Philidor Rx Services, and has taken heat for its drug-pricing practices.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES